Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026

Peptide Comparison

MK-677 vs CJC-1295 + Ipamorelin

Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.

Data-derived verdict

MK-677 has stronger documented evidence (Phase 3 (not approved)) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

Generated from catalog evidence-tier data, not editorial judgment. Both compounds share at least one mechanism class and this verdict reads the catalogued evidence tier of each, not specific trial nuance.

Evidence at a glance

MK-677

Phase 3 (not approved)

CJC-1295 + Ipamorelin

Anecdotal + Animal Studies

FDA-approved   Phase 3   Phase 2 / approved abroad   Anecdotal + animal   Preclinical / flagged

Side-by-side

MK-677 CJC-1295 + Ipamorelin
Class Oral non-peptide ghrelin receptor agonist GHRH analog + selective GHRP blend (GH-secretagogue stack)
Drug class Growth Hormone Secretion Growth Hormone Secretion
Mechanism GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm).
Route Oral SC injection
Half-life ~24 hrs CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs
Dosage (research) 12.5 mg oral daily (community starting dose to mitigate water retention and appetite increase, escalate to label dose 25 mg/day per MK-0677-014 Phase 3 protocol) 100 mcg of each component SC nightly (5 nights/wk); some protocols use 200 mcg of each pre-sleep. Cycle 8-12 weeks on / 4 weeks off
Evidence tier Phase 3 (not approved) Anecdotal + Animal Studies
Research depth 120 indexed (PubMed 97 · CT 8 · EPMC 15) 5 indexed (PubMed 0 · CT 0 · EPMC 5)
Availability Research Chemical Compounding Restricted
Reported risks Increased hunger; water retention; insulin resistance risk; lethargy; CHF risk (elderly trials) Receptor desensitisation with chronic daily dosing; mild water retention; injection site reactions; theoretical IGF-1 elevation with high-frequency dosing; not FDA-approved for any indication

Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.

Frequently asked questions

Should I pick MK-677 or CJC-1295 + Ipamorelin?

MK-677 has stronger documented evidence (Phase 3 (not approved)) than CJC-1295 + Ipamorelin (Anecdotal + Animal Studies) while both occupy the gh-secretagogue class. When clinical-evidence tier is the deciding factor, MK-677 is the safer pick. CJC-1295 + Ipamorelin may still fit a specific research framing the higher-evidence option does not cover: cost, dosing convenience, jurisdictional access, or a particular off-label use case.

What is the difference between MK-677 and CJC-1295 + Ipamorelin?

MK-677 is classed as Oral non-peptide ghrelin receptor agonist; CJC-1295 + Ipamorelin is classed as GHRH analog + selective GHRP blend (GH-secretagogue stack). Reported mechanism: MK-677, GHS-R1a agonist; stimulates pulsatile GH/IGF-1 release; orally bioavailable spiropiperidine; CJC-1295 + Ipamorelin, Dual-receptor stimulation: CJC-1295 (no-DAC) binds the pituitary GHRH receptor while Ipamorelin agonises the ghrelin / GHS-R1a receptor. Co-administration amplifies the natural GH pulse with a cleaner side-effect profile vs GHRP-2/6 (negligible cortisol or prolactin rise from the GHRP arm). Reported half-life: MK-677, ~24 hrs; CJC-1295 + Ipamorelin, CJC-1295 no-DAC ~30 min; Ipamorelin ~2 hrs. Routes in published studies: MK-677, Oral; CJC-1295 + Ipamorelin, SC injection.

Which has stronger evidence, MK-677 or CJC-1295 + Ipamorelin?

MK-677 has the stronger evidence base on PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. MK-677 is graded Phase 3 (not approved), with 5 cited sources on its reference page and 120 indexed studies. CJC-1295 + Ipamorelin is graded Anecdotal + Animal Studies, with 3 cited sources on its reference page and 5 indexed studies.

Which is more accessible, MK-677 or CJC-1295 + Ipamorelin?

Neither MK-677 nor CJC-1295 + Ipamorelin is an FDA-approved drug. Catalog status: MK-677, Research Chemical; CJC-1295 + Ipamorelin, Compounding Restricted. FDA lists MK-677 in category 2 of its bulk-substance compounding policy (503A; 503B, added 503A: September 29, 2023 503B: December 29, 2022).

Are MK-677 and CJC-1295 + Ipamorelin ever combined?

MK-677 and CJC-1295 + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.

Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.

Loading interactive view…